HHS Sets a Federal Kidney Care Agenda Around Earlier Detection and Transplant Access
The Department of Health and Human Services has launched a Kidney Care National Plan that aims to move U.S. kidney policy away from late-stage rescue care and toward earlier intervention, broader treatment choice, and stronger transplant access. The plan is built around a simple but consequential premise: kidney disease is too often recognized only after major nephron loss has already occurred, when the clinical path narrows to dialysis or transplantation and the chance to preserve native kidney function has largely slipped away.
Kidney disease affects an estimated 37 million American adults, yet most people with the condition do not know they have it. In practice, that diagnostic gap pushes patients into care when creatinine has already worsened, proteinuria has already signaled damage, and the biologic process of progressive nephron dropout is already well underway. Once that trajectory is established, the burden on patients becomes cumulative and relentless, with dialysis dependence and transplant evaluation often arriving after years of silent injury.
The new plan is framed around three priorities: preventing kidney failure, improving dialysis care and patient choice, and reforming transplantation. Each of those pillars reflects a different stage of disease, but they share the same clinical logic. Earlier recognition allows blood pressure control, proteinuria reduction, metabolic risk management, and newer kidney-directed therapies to be deployed before irreversible scarring dominates the picture.
Kidney failure rarely arrives in a single step.
Prevention Strategy Puts Earlier Kidney Disease Detection at the Center
The prevention component is the most direct response to the long-standing problem of delayed diagnosis. HHS says the plan will support earlier detection, earlier intervention, and the development of treatments and technologies that can slow or stop progression. In nephrology, that means paying closer attention to the cardiovascular-kidney-metabolic connection, where obesity, diabetes, hypertension, dyslipidemia, and chronic inflammation feed the same pathophysiology that damages glomeruli and tubulointerstitial tissue.
The plan also ties prevention to the KidneyX Prize Competition: Nourishing Kidney Health, through which HHS is investing up to $4.67 million with the American Society of Nephrology. The prize is intended to advance earlier cardiovascular-kidney-metabolic risk identification and practical nutrition and lifestyle strategies that can slow chronic kidney disease progression, preserve kidney function, and improve quality of life. In clinical terms, that focus matters because dietary sodium, protein handling, weight control, and metabolic risk reduction all influence the hemodynamic stress that accelerates kidney decline.
Dialysis Reform Brings Choice, Home Care, and Market Competition Into View
The dialysis portion of the plan centers on competition, lower barriers to entry for new providers and treatments, and wider access to home-based care. Those are not abstract policy goals. Dialysis remains a life-sustaining therapy with a heavy symptom burden, and the setting of care can shape fatigue, vascular access complications, infection risk, treatment flexibility, and the daily autonomy of patients who are already managing severe chronic illness.
Home dialysis can give selected patients more control over scheduling and may better align therapy with work, family, and transportation realities. A policy framework that expands that option while also encouraging innovation in the dialysis market seeks to alter a system that has often been rigid and reactive. By emphasizing quality of life alongside outcomes, the plan acknowledges that kidney care is judged not only by survival but by the lived burden of treatment.
Transplant Policy Moves Toward Greater Access and Faster Living Donation
The transplantation pillar may carry the greatest immediate bedside consequence for patients with kidney failure. HHS says it will pursue a National Transplant Expansion Strategy that builds on the 2019 executive order on advancing American kidney health and is intended to make living donation easier and more accessible. Living donor transplantation remains one of the strongest options for many patients because it can shorten wait times and offer better graft function than prolonged time on dialysis for appropriate candidates.
Federal agencies are also pushing a set of structural changes designed to widen access. Following passage of the HOLD Act in February 2026, HRSA revised eligibility guidelines for the Living Organ Donor Reimbursement Program and streamlined the process within the year. Financial barriers are a major deterrent to living donation, and reimbursement policies can determine whether a willing donor can actually proceed without absorbing untenable travel, lodging, wage, or related costs.
The plan also emphasizes transplant system accountability. HHS has moved to decertify organ procurement organizations that did not meet federal standards for safety, performance, and accountability after reviews identified persistent patient safety failures and insufficient improvement despite oversight and corrective action. In transplant medicine, process reliability is inseparable from patient safety; a system that mishandles procurement or coordination can waste organs, delay transplants, and erode trust in a field where every usable kidney matters.
New Kidney Therapies and Regulatory Pathways Are Already Changing Practice
The plan is being launched alongside a burst of federal activity around new kidney therapeutics. Over the last 12 months, FDA expanded the treatment landscape for serious kidney diseases with approvals that included the first FDA-approved treatment for certain patients with focal segmental glomerulosclerosis, the first treatment for adults with complement 3 glomerulopathy to reduce proteinuria, and new therapies for immunoglobulin A nephropathy and idiopathic nephrotic syndrome. Several of these products received Orphan Drug, Breakthrough Therapy, Priority Review, or accelerated approval designations.
Those regulatory pathways matter because they signal a recognition that severe kidney diseases, including rare glomerular disorders, often progress before large outcome trials can fully mature. In many of these conditions, reduction in proteinuria is not just a laboratory metric; it is a biologically meaningful marker of decreased glomerular injury and a potential proxy for slower progression toward kidney failure. Faster access to therapies may allow nephrologists to act earlier in diseases that were previously managed with limited options.
Economic Signals Suggest Policy Can Alter the Care Trajectory
An analysis released by the Office of the Assistant Secretary for Planning and Evaluation found that kidney transplants grew faster after the 2019 executive order, with roughly 2,000 additional kidney transplants per year and projected economic benefits reaching $200 billion through 2040. Those figures point to something clinicians have long understood at the bedside: transplant access is not only a quality-of-life issue, but also a system-wide economic one. Preventing or shortening dialysis dependence can change resource use across the entire care continuum.
The challenge now is execution. Earlier detection still depends on screening, follow-up, and timely referral. Dialysis reform still depends on whether payment and market changes translate into real access. Transplant reform still depends on whether living donation becomes less burdensome and whether oversight can prevent procurement failures without slowing the system to a crawl.
The Kidney Care National Plan lays out a federal direction for the next phase of kidney policy, but the hard clinical work remains in whether those goals reach patients before their kidneys fail, not after.